Core Points - Invivyd, Inc. announced a public offering of 74,811,404 shares of common stock at $0.52 per share, along with pre-funded warrants for 21,342,442 shares at $0.5199 each, aiming for gross proceeds of approximately $50 million [1][3] - The offering is expected to close on or about August 22, 2025, subject to customary closing conditions [1] - Cantor is acting as the sole book-running manager for the offering [2] Use of Proceeds - The net proceeds will be utilized for trial protocol development and advancement of the VYD2311 clinical program, research and development for pipeline programs including RSV and measles, and efforts related to monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome [3] Company Overview - Invivyd, Inc. is a biopharmaceutical company focused on protection against serious viral infectious diseases, starting with SARS-CoV-2, and has a proprietary technology platform for developing antibodies [7]

Core Viewpoint - Invivyd, Inc. has initiated an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of the shares sold at the public offering price [1][3]. Group 1: Offering Details - The offering is subject to market conditions and there is no assurance regarding its completion or the actual size and terms [1]. - Cantor is acting as the sole book-running manager for the offering [2]. - The offering will be conducted under a shelf registration statement filed with the SEC, which was declared effective on October 5, 2022 [4]. Group 2: Use of Proceeds - Invivyd plans to use the net proceeds from the offering for trial protocol development, advancement of the VYD2311 clinical program, and research related to its pipeline programs, including RSV and measles [3]. - Additional uses of the proceeds include efforts related to monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, as well as general corporate purposes [3]. Group 3: Company Background - Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2 [7]. - The company utilizes a proprietary technology platform to develop and adapt antibodies, and received emergency use authorization for a monoclonal antibody in March 2024 [7].

Core Viewpoint - Invivyd, Inc. will host a conference call on May 15, 2025, to discuss its Q1 2025 financial results and recent business highlights [1]. Company Overview - Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2 [3]. - The company utilizes a proprietary integrated technology platform that is unique in the industry for assessing, monitoring, developing, and adapting to create best-in-class antibodies [3]. - In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody in its pipeline of innovative antibody candidates [3].